Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Table 2 Estimated median time to relapse

Canakinumab Dose regimen	No. of subjects	No. of periods	Median time to relapse (days)	95% confidence interval
2 mg/kg s.c.	4	22	48.6	29.3 to 67.9
2 mg/kg s.c. + rescue i.v.	2**	11	51.7	27.0 to 76.5

** Two subjects received rescue medication for some periods. In one out of these two pediatric patients, data of periods in which rescue medication was not given were analyzed with the 2 mg/kg s.c. group, while data of periods in which rescue medication was given were analyzed separately with the 2 mg/kg s.c. + rescue i.v. group.